Literature DB >> 29270734

Novel actinomycin group compound from newly isolated Streptomyces sp. RAB12: isolation, characterization, and evaluation of antimicrobial potential.

Balaji Baburao Rathod1,2, Ravichandra Korasapati1,2, Prabhakar Sripadi3, Prakasham Reddy Shetty4.   

Abstract

Streptomyces sp. RAB12 having potential to produce novel actinomycin group compounds was isolated from soil samples collected from CSIR-Indian Institute of Chemical Technology, Hyderabad, India, garden premises using International Streptomycetes Project (ISP) protocols. The 16S rRNA sequence of the strain RAB12 exhibited identity with Streptomyces sp. 13647M and the sequence was deposited in NCBI under the accession number KY 203650 while the strain RAB12 was deposited in The Microbial Type Culture Collection and Gene Bank (MTCC) with accession number MTCC 12747. Cell-free extract of this novel strain revealed two bioactive principles viz., RSP 01 and RSP 02. HR-MS analysis indicated a molecular mass of 1269.61 and 1270.63 m/z g/mol for RSP 01 and RSP 02, respectively. Proton 1H, 13C NMR, 2D NMR and mass spectroscopy analysis revealed a similar fingerprint to that actinomycin D except for a peak at δH3.59 J (1H NMR) and δ 208.88 (13C NMR) for RSP 01 compound suggesting the presence of keto carbonyl at 5-oxo position on the proline moiety which is absent in actinomycin D. Purified RSP 02 depicted a similarity with RSP 01 except a peak in the 1H proton NMR at δH 3.81 J. HR-ESI mass spectra confirmed the molecular formulae for RSP 01 and RSP 02 as C62H84N12O17 and C62H86N12O17, respectively. Antimicrobial activity profile revealed higher antimicrobial activity against bacterial strains (Pseudomonas aeruginosa, Micrococcus luteus, Staphylococcus aureus, Salmonella typhi, and Bacillus subtilis) and Candida albicans compared to standard actinomycin D. MIC and MBC for RSP 01 were observed to be 0.0039 and 0.0078 (μg/ml) against C. albicans, while for actinomycin D, it was found to be 0.031 and 0.62 (μg/ml), respectively indicating a tenfold higher potency. Thus, these RSP 01 and RSP 02 compounds from Streptomyces sp. RAB12 may be promising candidates for industrial and clinical applications.

Entities:  

Keywords:  Actinomycin; MBC; MIC; NMR and mass spectroscopy

Mesh:

Substances:

Year:  2017        PMID: 29270734     DOI: 10.1007/s00253-017-8696-4

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  6 in total

1.  Giving Drugs a Second Chance: Antibacterial and Antibiofilm Effects of Ciclopirox and Ribavirin against Cystic Fibrosis Pseudomonas aeruginosa Strains.

Authors:  Giovanni Di Bonaventura; Veronica Lupetti; Simone De Fabritiis; Alessandra Piccirilli; Annamaria Porreca; Marta Di Nicola; Arianna Pompilio
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

2.  Gut bacteria of Cuora amboinensis (turtle) produce broad-spectrum antibacterial molecules.

Authors:  Noor Akbar; Naveed Ahmed Khan; K Sagathevan; Mazhar Iqbal; Abdul Tawab; Ruqaiyyah Siddiqui
Journal:  Sci Rep       Date:  2019-11-18       Impact factor: 4.379

Review 3.  Promising bioactive compounds from the marine environment and their potential effects on various diseases.

Authors:  Akash Karthikeyan; Abey Joseph; Baiju G Nair
Journal:  J Genet Eng Biotechnol       Date:  2022-01-26

Review 4.  Secondary Metabolites of Actinomycetes and their Antibacterial, Antifungal and Antiviral Properties.

Authors:  Katarzyna Jakubiec-Krzesniak; Aleksandra Rajnisz-Mateusiak; Adam Guspiel; Joanna Ziemska; Jolanta Solecka
Journal:  Pol J Microbiol       Date:  2018

Review 5.  Antimicrobial Peptides: a New Frontier in Antifungal Therapy.

Authors:  Giuseppe Buda De Cesare; Shane A Cristy; Danielle A Garsin; Michael C Lorenz
Journal:  mBio       Date:  2020-11-03       Impact factor: 7.867

6.  Antimicrobial compounds were isolated from the secondary metabolites of Gordonia, a resident of intestinal tract of Periplaneta americana.

Authors:  Yan Ma; Minhua Xu; Hancong Liu; Tiantian Yu; Ping Guo; Wenbin Liu; Xiaobao Jin
Journal:  AMB Express       Date:  2021-07-30       Impact factor: 3.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.